LPL Financial’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-90,000
Closed -$148K 5905
2025
Q3
$148K Buy
90,000
+60,000
+200% +$66.7K ﹤0.01% 5428
2025
Q2
$21.9K Buy
+30,000
New +$25.9K ﹤0.01% 5461

Other funds holding CHRS

LPL Financial's CHRS Position: Q2 2026 in Review

LPL Financial reduced its Coherus Oncology (CHRS) stake by 60% in Q2 2026, selling an estimated $119K and leaving 48,167 shares worth $67.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5987.

LPL Financial first reported a position in CHRS in Q4 2023 and has held it in 11 quarters since. The position peaked at $359K in Q3 2025. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • LPL Financial held 48,167 shares of Coherus Oncology worth $67.4K as of Q2 2026.
  • LPL Financial sold 72,629 Coherus Oncology shares in Q2 2026, an estimated $119K.
  • Coherus Oncology made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5987 holding.
  • LPL Financial first reported a position in Coherus Oncology in Q4 2023 and has held it in 11 quarters since.
  • LPL Financial's Coherus Oncology position peaked at $359K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.